1. Home
  2. BGX vs GBIO Comparison

BGX vs GBIO Comparison

Compare BGX & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Long Short Credit Income Fund

BGX

Blackstone Long Short Credit Income Fund

HOLD

Current Price

$11.84

Market Cap

151.0M

Sector

Finance

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.47

Market Cap

35.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGX
GBIO
Founded
2010
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.0M
35.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BGX
GBIO
Price
$11.84
$5.47
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$10.67
AVG Volume (30 Days)
67.9K
40.1K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
10.34%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$15,270,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.69
$3.00
52 Week High
$12.44
$13.00

Technical Indicators

Market Signals
Indicator
BGX
GBIO
Relative Strength Index (RSI) 50.32 51.71
Support Level $11.77 $5.22
Resistance Level $11.90 $5.64
Average True Range (ATR) 0.11 0.25
MACD 0.01 0.05
Stochastic Oscillator 65.22 67.19

Price Performance

Historical Comparison
BGX
GBIO

About BGX Blackstone Long Short Credit Income Fund

Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: